What is unique about an Immunotherapy Clinical Trial at Karmanos Cancer Institute?
Karmanos Cancer Institute offers a unique treatment for fighting cancer. Karmanos Cancer Institute is the only cancer center in the nation that offers bispecific antibody-targeted T cell immunotherapy.
Antibody-targeted cellular immunotherapy is a treatment that combines cell-based and antibody-based therapy to help “clean up” remaining cancerous cells after the patient has gone through chemotherapy. T cells are “armed” with a bispecific antibody, which is a protein that has been created from two protein antibodies to bind to two targets at the same time. The first target is the T cell (a type of white blood cell) and the second is a protein on the surface of the tumor cell. After the T cells are armed, the T cells are put back into the patient through an IV.
Armed T cells are targeted to the tumor cells and will kill them when they come in contact with them. Thus, the patient is using their own immune system to fight cancer and possibly lessen the chances of cancer relapse.
This type of therapy is currently under investigation for the treatment of breast cancer, non-Hodgkin’s lymphoma, and multiple myeloma. The bispecific antibody OKT3 x Herceptin® is used to treat breast cancer tumors and the bispecific antibody OKT3 x Rituxan® is used to treat non-Hodgkin’s lymphoma and multiple myeloma. Thus far, data from these trials strongly suggest that T cell therapy along with a standard chemotherapy regimen may improve overall survival as compared to patients who only receive chemotherapy treatment.
This therapy has been approved for investigation and has been suggested to target both HER2/neu positive and HER2/neu negative breast tumors. Herceptin® (Trastuzamab), the current standard antibody-based therapy for breast cancer is only approved for HER2/neu positive tumors which only account for about 20% of the women who have breast cancer.
Antibody-targeted cellular immunotherapy is approved for investigation in all breast cancer patients and is suggested to benefit most women with breast cancer regardless of their HER2/neu status. Karmanos Cancer Institute is the only institution that currently offers this immune boosting therapy.
Karmanos Physicians Participating in Bispecific Antibody-Targeted T Cell Immunotherapy Clinical Trials
Zaid S. Al-Kadhimi, M.D. - Hematology and Medical Oncology
Clinical Trial Disease site(s): Breast
Lawrence G. Lum, M.D., D.Sc. Oncology/Medicine/Immunology/BMT/Pediatrics
Clinical Trial Disease site(s): Breast cancer, non-Hodgkin’s lymphoma, multiple myeloma, and pancreatic and GI cancer
Jeffrey Zonder, M.D. Hematology and Medical Oncology
Clinical Trial Disease site(s): Multiple Myeloma
Find an Immunotherapy Clinical Trial at Karmanos Cancer Institute
Click the title links to read more about immunotherapy clinical trials at Karmanos Cancer Institute.
WSU-2009-085 (NCT01022138): A Phase II Study of anti-CD3 x anti-HER2/neu Activated T Cells in Women with HER2/neu (0, 1+, or 2+) Metastatic Breast Cancers
PI/Co-PI - L.G. Lum, M.D., D.Sc.
Tumor Site - Breast
WSU-2010-056 (NCT01147016): A Phase II Study of Anti-CD3 x Anti-HER2/neu (Her2Bi) Armed Activated T Cells (ATC) after Neoadjuvant Chemotherapy in Women with HER2/neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers
PI/Co-PI - L.G. Lum, M.D., D.Sc. and Z. Al-Kadhimi, M.D.
Tumor Site - Breast
WSU-2008-106 (NCT00938626): Induction of Anti-Myeloma Stem Cell Immunity with Infusions of Autologous Activated T Cells Armed with OKT3 x Rituxan (anti-CD3 x anti-CD20) Bispecific Antibody (CD20Bi) (Phase I)
PI/Co-PI - J. Zonder, M.D. and L.G. Lum, M.D., D.Sc.
For More Information
- Click here to find a Clinical Trial.
- Speak with your physician.
- Call 313-576-8384 or e-mail firstname.lastname@example.org.
- Call (800) 4-CANCER (1-800-422-6237), the National Cancer Institute's Cancer Information Service, or visit its website: www.cancer.gov.
- Oncology by Oncologystat.